SCHEMBL7998301

SCHEMBL7998301

Cc1ccc(O)c(-c2cc(-c3cccc(F)c3)[nH]n2)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.81
ALOX15 P16050 10/20 0.81
SMN1; SMN2 Q16637 8/20 0.81
HPGD P15428 8/20 0.81
NPSR1 Q6W5P4 5/20 0.81
HSP90AA1 P07900 2/20 0.81
KMT2A Q03164 13/20 0.71
MEN1 O00255 12/20 0.71
RAB9A P51151 9/20 0.71
NPC1 O15118 9/20 0.71
NFKB1 P19838 5/20 0.71
NFKB2 Q00653 5/20 0.71
RELA Q04206 5/20 0.71
CASP3 P42574 3/20 0.71
SENP8 Q96LD8 3/20 0.71
SENP7 Q9BQF6 3/20 0.71
SENP6 Q9GZR1 3/20 0.71
CASP1 P29466 1/20 0.71
POLB P06746 1/20 0.65
LMNA P02545 4/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL404975 0.91 KMT2A (0.81) MAPTALOX15SMN1; SMN2HPGDNPSR1
SCHEMBL22415561 0.90 MAPT (0.66) MAPTALOX15SMN1; SMN2HPGDNPSR1
SCHEMBL10357789 0.85 KMT2A (0.69) MAPTALOX15SMN1; SMN2HPGDNPSR1
SCHEMBL960647 0.85 HPGD (0.72) MAPTALOX15SMN1; SMN2HPGDNPSR1
SCHEMBL15425113 0.85 MAPT (0.62) MAPTALOX15SMN1; SMN2HPGDNPSR1
SCHEMBL7995544 0.84 ALOX15 (0.80) MAPTALOX15SMN1; SMN2HPGDNPSR1
SCHEMBL10357439 0.82 KMT2A (0.68) MAPTALOX15SMN1; SMN2HPGDNPSR1
SCHEMBL22415615 0.81 MAPT (0.59) MAPTALOX15SMN1; SMN2HPGDNPSR1
SCHEMBL22415335 0.80 MAPT (0.56) MAPTALOX15SMN1; SMN2HPGDNPSR1
SCHEMBL403442 0.80 KMT2A (0.66) MAPTALOX15SMN1; SMN2HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307381-B1 NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2021-01-13 EP disclosed
US-10435373-B2 Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2019-10-08 US disclosed
US-20160185730-A1 DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2016-06-30 US disclosed
US-20160185730-A1 DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2016-06-30 US disclosed
EP-2687513-A1 Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases Ludwig-Maximilians-Universität München (DE) 2014-01-22 EP disclosed
EP-2684873-A1 DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES Ludwig-Maximilians-Universität München (DE) 2014-01-15 EP disclosed
US-20120184583-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-19 US disclosed
US-20120184583-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-19 US disclosed
US-20110293520-A1 NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. 2011-12-01 US disclosed
US-20110293520-A1 NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. 2011-12-01 US disclosed
US-20100144798-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-10 US disclosed
US-20100144798-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-10 US disclosed
WO-2010000372-A2 NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185730-A1 DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES PARK7, APP, HYPK MAPT 8/4885ALOX15 4636/4885SMN1; SMN2 504/4885
US-20120184583-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 MAPT 4385/4885ALOX15 3215/4885SMN1; SMN2 4852/4885
US-20100144798-A1 Modulators of ATP-Binding Cassette Transporters CFTR, ABCB1, ABCC2 MAPT 4385/4885ALOX15 3215/4885SMN1; SMN2 4852/4885
US-20110293520-A1 NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES PARK7, HYPK, IK MAPT 40/4885ALOX15 4677/4885SMN1; SMN2 309/4885
US-10435373-B2 Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases PARK7, APP, HYPK MAPT 8/4885ALOX15 4636/4885SMN1; SMN2 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.